In pancreatic cancer, HAT1 was shown to function as an important regulator in cancer immunity through transcriptional upregulation of PD-L1 in tumor cells, indicating that HAT1 could be used as a novel diagnostic and prognostic marker in immune checkpoint blockade therapy (Fan et al., 2019). The gene discussed is HAT1; the disease is pancreatic neoplasm.